流感的大流行新型冠状病毒据统计，目前全球已有超过6370万人感染，超过140万人死亡实时数据由约翰·霍普金斯大学系统科学与工程中心编辑。

美国报告超过18万新病例

根据约翰·霍普金斯大学的实时统计，周二美国有180，098例新的新冠肺炎确诊病例。

这是该国连续第29天报告超过10万例新诊断的感染。周二的数字低于上周五205，557例新病例的峰值。

周二，全国范围内又有2597人死于新冠肺炎，略低于4月15日2609人的历史最高水平。

新冠肺炎的数据在未来几天和几周可能会出现偏差，因为感恩节后的报告可能会滞后，接下来可能会有大量的假期积压。

弗雷德里克·j·布朗/法新社，通过盖蒂图像

人们在加州蒙特雷公园加菲尔德医疗中心的急诊室外等待

根据约翰·霍普金斯的数据，自大流行开始以来，美国共有13，725，917人被诊断出患有新冠肺炎病，其中至少270，669人已经死亡。这些案件包括来自美国所有50个州、华盛顿特区和其他美国领土的人以及被遣返的公民。

截至3月底，随着第一波大流行袭击，该国大部分地区处于封锁状态。到5月20日，美国所有州都开始取消家庭订单和其他限制措施，以遏制新型冠状病毒的传播。该国病例的日常增长在夏季回升之前的几周内一直徘徊在2万例左右。

从8月中旬到10月初，这一数字徘徊在4万至5万左右，然后再次飙升至创纪录水平，11月4日首次突破10万，11月27日首次达到20万。

英国授权辉瑞/生物技术公司疫苗，下周开始推广

美国制药巨头辉瑞公司及其德国合作伙伴生物技术公司开发的新冠肺炎疫苗已获准在英国使用。

英国卫生和社会保障部周三宣布，已接受该国药品监管机构的建议，授予辉瑞/生物技术公司疫苗BNT162b2的临时紧急使用授权。药品和保健产品管理局(MHRA)得出结论，该疫苗符合其安全、质量和有效性标准。

“从下周开始，这种疫苗将在英国全境提供，”卫生和社会保障部发言人在一份声明中说，并补充说，公共资助的医疗保健系统国家卫生服务局(National Health Service)“将开始投入大量准备工作，为所有有资格接种疫苗的人提供护理和支持。”

由马里兰大学医学院通过美联社提供

2020年5月4日，马里兰大学医学院提供的档案照片显示

英国是世界上第一个批准辉瑞/生物技术公司疫苗的国家。这两家公司周三在一份联合新闻稿中表示，他们预计未来几天和几周内全球将做出进一步的监管决定，并准备在等待授权或批准的情况下提供疫苗剂量。

辉瑞董事长兼首席执行官艾伯特·布尔拉在一份声明中说:“今天英国的紧急使用授权标志着对抗新冠肺炎的历史性时刻。”。“由于我们预计将获得进一步的授权和批准，我们正以同样的紧迫感致力于在全球安全供应高质量的疫苗。随着成千上万的人被感染，在结束这场毁灭性的流行病的集体竞赛中，每天都很重要。”

MHRA是根据滚动提交的资料提出建议的，其中包括第三阶段试验的数据，该试验证明疫苗的有效率为95%。辉瑞/生物技术公司的疫苗通常耐受性良好，迄今为止没有严重的安全问题报告。

乔尔·萨吉特/法新社，通过盖蒂图像

美国制药公司的商标旁边有一个瓶子，上面写着“新冠肺炎疫苗”

一旦获准紧急使用，辉瑞和生物技术公司已经同意向英国提供4000万剂BNT162b2。既然疫苗已经获得批准，两家公司将立即开始运送疫苗，预计第一批疫苗将在未来几天抵达英国。根据新闻稿，其余剂量将分阶段到达，预计在2021年完成交付。

辉瑞和生物技术公司表示，他们的疫苗在英国的分发将根据疫苗接种和免疫联合委员会(Joint Committee on Budgeting and Impensation)的指导意见中确定的人群进行优先排序。该委员会是一个独立的专家组，就免疫问题向英国政府提供建议。

“英国的紧急使用授权将标志着试验之外的公民第一次有机会接种新冠肺炎疫苗，”生物技术公司首席执行官兼联合创始人乌古尔·萨欣在一份声明中说。“我们相信，英国疫苗接种计划的推出将减少高风险人群中住院的人数。”

这些公司还向美国食品和药物管理局提交了紧急使用授权申请，并向欧洲药品管理局提交了有条件营销授权申请。

美国因新冠肺炎住院的人数接近99K

根据新冠肺炎跟踪项目，美国目前因新冠肺炎住院的人数周二创下新高，达到98，691人。

该项目称，印第安纳州、内华达州和南达科塔州报告称，目前每百万人中有500多人住院。

COVID跟踪项目表示，这些数据仍受到感恩节假期的干扰，因为几个州报告了超过一天的数据，其他州仅在周二公布了部分更新。

报告指出，新冠肺炎每日死亡人数在节后下降后开始反弹，周二报告了2473人。

Coronavirus live updates: UK authorizes Pfizer/BioNTech vaccine, rollout to begin next week

A pandemic of thenovel coronavirushas now infected more than 63.7 million people and killed over 1.4 million worldwide, according toreal-time datacompiled by the Center for Systems Science and Engineering at Johns Hopkins University.

US reports over 180,000 new cases

There were 180,098 new cases of COVID-19 confirmed in the United States on Tuesday, according to a real-time count kept by Johns Hopkins University.

It's the 29th straight day that the country has reported over 100,000 newly diagnosed infections. Tuesday's count is down from a peak of 205,557 new cases last Friday.

An additional 2,597 fatalities from COVID-19 were also registered nationwide on Tuesday, just under the all-time high of 2,609 new deaths on April 15.

COVID-19 data may be skewed in the coming days and weeks due to possible lags in reporting over Thanksgiving followed by a potentially very large backlog from the holiday.

A total of 13,725,917 people in the United States have been diagnosed with COVID-19 since the pandemic began, and at least 270,669 of them have died, according to Johns Hopkins. The cases include people from all 50 U.S. states, Washington, D.C. and other U.S. territories as well as repatriated citizens.

Much of the country was under lockdown by the end of March as the first wave of pandemic hit. By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country's cases then hovered around 20,000 for a couple of weeks before shooting back up over the summer.

The numbers lingered around 40,000 to 50,000 from mid-August through early October before surging again to record levels, crossing 100,000 for the first time on Nov. 4 and reaching 200,000 for the first time on Nov. 27.

UK authorizes Pfizer/BioNTech vaccine, rollout to begin next week

A COVID-19 vaccine developed by U.S. pharmaceutical giant Pfizer and its German partner BioNTech has been approved for use in the United Kingdom.

The U.K. Department of Health and Social Care announced Wednesday that it has accepted the recommendation from the country's drug regulator to grant a temporary authorization for emergency use of the Pfizer/BioNTech vaccine, called BNT162b2. The Medicines and Healthcare products Regulatory Agency (MHRA) concluded that the vaccine met its standards of safety, quality and effectiveness.

"The vaccine will be made available across the U.K. from next week," a Department of Health and Social Care spokesperson said in a statement, adding that the National Health Service, the publicly-funded healthcare system, "will begin putting their extensive preparations into action to provide care and support to all those eligible for vaccination."

The United Kingdom is the first country in the world to approve the Pfizer/BioNTech vaccine. The companies said in a joint press release Wednesday that they are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses pending authorizations or approvals.

"Today’s Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19," Pfizer chairman and CEO Albert Bourla said in a statement. "As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world. With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic."

The MHRA made its recommendation based on a rolling submission, including data from the Phase 3 trial which demonstrated a vaccine efficacy rate of 95%. The Pfizer/BioNTech vaccine was generally well tolerated, with no serious safety concerns reported to date.

Pfizer and BioNTech had already agreed to supply the United Kingdom with 40 million doses of BNT162b2 once authorized for emergency use. Now that the vaccine is authorized, the companies will immediately begin delivering doses, the first of which are expected to arrive on U.K. soil in the coming days. The rest of the doses will arrive in stages, with complete delivery fulfillment expected in 2021, according to the press release.

Pfizer and BioNTech said the distribution of their vaccine in the United Kingdom will be prioritized according to the populations identified in guidance from the Joint Committee on Vaccination and Immunisation, an independent expert group that advises the U.K. government on immunization.

"The Emergency Use Authorization in the U.K. will mark the first time citizens outside of the trials will have the opportunity to be immunized against COVID-19," BioNTech CEO and co-founder Ugur Sahin said in a statement. "We believe that the roll-out of the vaccination program in the U.K. will reduce the number of people in the high-risk population being hospitalized."

The companies have also filed a request for emergency use authorization with the U.S. Food and Drug Administration and have submitted an application for conditional marketing authorization with the European Medicines Agency.

Number of people hospitalized with COVID-19 nearly 99K in US

The number of peoplecurrently hospitalized with COVID-19 in the U.S. reached a new high on Tuesday, with98,691 hospitalizations, according to the COVID-19 Tracking Project.

Indiana, Nevada and South Dakota are reporting more than500 currently hospitalized per million people, the project said.

The data is still being disrupted by the Thanksgiving holiday, as several states reported data for more than one day and othersonly published partial updates on Tuesday, the COVID Tracking Project said.

The number of daily deaths from COVID-19 is starting to rebound after a post-holiday drop, it noted, with 2,473 reported on Tuesday.